Similar articles for PMID: 30283980

Year	Number of Results
2011	1
2012	3
2013	7
2014	23
2015	19
2016	15
2017	32
2018	24
2019	29
2020	19
2021	32
2022	35
2023	13
2024	0

1

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.

Kosaka T, Hongo H, Watanabe K, Mizuno R, Kikuchi E, Oya M. Kosaka T, et al. Cancer Chemother Pharmacol. 2018 Dec;82(6):1061-1066. doi: 10.1007/s00280-018-3698-1. Epub 2018 Oct 3. Cancer Chemother Pharmacol. 2018. PMID: 30283980 Free PMC article.

2

No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Med Oncol. 2017 Aug;34(8):141. doi: 10.1007/s12032-017-1005-3. Epub 2017 Jul 17. Med Oncol. 2017. PMID: 28718092 Clinical Trial.

3

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.

Pobel C, Auclin E, Teyssonneau D, Laguerre B, Cancel M, Boughalem E, Noel J, Brachet PE, Maillet D, Barthelemy P, Helissey C, Thibault C, Oudard S. Pobel C, et al. Cancer Med. 2021 Sep;10(18):6304-6309. doi: 10.1002/cam4.4172. Epub 2021 Aug 12. Cancer Med. 2021. PMID: 34382352 Free PMC article.

4

Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.

Ito T, Kanao K, Takahara K, Ando R, Yasui T, Shiroki R, Sumitomo M, Miyake H. Ito T, et al. Anticancer Res. 2019 Jun;39(6):3089-3094. doi: 10.21873/anticanres.13444. Anticancer Res. 2019. PMID: 31177153

5

PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.

Hammerer P, Al-Batran SE, Windemuth-Kieselbach C, Keller M, Hofheinz RD. Hammerer P, et al. World J Urol. 2018 Mar;36(3):375-381. doi: 10.1007/s00345-017-2138-x. Epub 2018 Jan 5. World J Urol. 2018. PMID: 29305637

6

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.

Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F. Meisel A, et al. Eur J Cancer. 2016 Mar;56:93-100. doi: 10.1016/j.ejca.2015.12.009. Epub 2016 Jan 30. Eur J Cancer. 2016. PMID: 26829012 Clinical Trial.

7

Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2018 Jul;38(7):4179-4185. doi: 10.21873/anticanres.12711. Anticancer Res. 2018. PMID: 29970547

8

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Al Nakouzi N, et al. Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2. Eur Urol. 2015. PMID: 24837187

9

Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.

Yasuoka S, Yuasa T, Ogawa M, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J. Yasuoka S, et al. Anticancer Res. 2019 Oct;39(10):5803-5809. doi: 10.21873/anticanres.13784. Anticancer Res. 2019. PMID: 31570485

10

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS. Mehra N, et al. Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28. Eur Urol. 2018. PMID: 29500065 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

203 results

Results by year